[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100478435":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":29,"overallOfficials":13,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":13,"id":61,"slug":13,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":13,"eligibilityCriteria":65,"healthyVolunteers":62,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":13,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":13,"overallStatus":42,"whyStopped":13,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Henry Ford Health System","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"non-infectious fever","non infectious fever defined as fever without identified infection that occurs up to 3 days prior and 10 days after the day of engraftment in patients on budesonide prophylaxis compared to patients who will not receive prophylaxis","30 days post stem cell transplant",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21,26],{"label":22,"type":23,"description":13,"interventionNames":24},"Budesonide","EXPERIMENTAL",[25],"Drug: Budesonide",{"label":27,"type":28,"description":13,"interventionNames":13},"nothing","NO_INTERVENTION",[30],{"type":31,"name":22,"description":32,"armGroupLabels":33,"otherNames":13},"DRUG","budesonide starting day 5 after transplant",[22],[35],{"name":36,"role":37,"phone":38,"phoneExt":13,"email":39},"shatha farhan","CONTACT","3137133910","sfarhan1@hfhs.org",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Detroit","Michigan","48202","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-83.04575,42.33143,{"lat":52,"lon":51},[55],{"name":36,"role":37,"phone":56,"phoneExt":13,"email":39},"313-916-5002",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"PRINCIPAL_INVESTIGATOR","Shatha Farhan","MD","100478435",false,"NCT05509933","Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* • Patients 18-80 years of age with a diagnosis of a hematological malignancy\n\n  * Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies\n\nExclusion Criteria:\n\n* • Patients enrolled in investigational clinical trials\n\n  * Sct for non hematologic malignancies","ALL","18 Years","80 Years",{"count":70,"type":71},110,"ESTIMATED","INTERVENTIONAL",[74],"PHASE3","The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.",[77],"Engraftment Syndrome","2026-04-29",{"date":80,"type":81},"2026-05-01","ACTUAL",{"date":83,"type":81},"2022-11-09",{"date":85,"type":71},"2027-12-30",{"name":5,"class":6},1]